JP2023525555A5 - - Google Patents

Info

Publication number
JP2023525555A5
JP2023525555A5 JP2022568853A JP2022568853A JP2023525555A5 JP 2023525555 A5 JP2023525555 A5 JP 2023525555A5 JP 2022568853 A JP2022568853 A JP 2022568853A JP 2022568853 A JP2022568853 A JP 2022568853A JP 2023525555 A5 JP2023525555 A5 JP 2023525555A5
Authority
JP
Japan
Prior art keywords
agonist
therapeutic agent
agonist according
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022568853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525555A (ja
JP7827640B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031806 external-priority patent/WO2021231447A1/en
Publication of JP2023525555A publication Critical patent/JP2023525555A/ja
Publication of JP2023525555A5 publication Critical patent/JP2023525555A5/ja
Priority to JP2025206113A priority Critical patent/JP2026048706A/ja
Application granted granted Critical
Publication of JP7827640B2 publication Critical patent/JP7827640B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022568853A 2020-05-12 2021-05-11 新規なil10アゴニストを含む治療剤 Active JP7827640B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025206113A JP2026048706A (ja) 2020-05-12 2025-11-27 新規なil10アゴニストおよびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023703P 2020-05-12 2020-05-12
US63/023,703 2020-05-12
PCT/US2021/031806 WO2021231447A1 (en) 2020-05-12 2021-05-11 Novel il10 agonists and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025206113A Division JP2026048706A (ja) 2020-05-12 2025-11-27 新規なil10アゴニストおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2023525555A JP2023525555A (ja) 2023-06-16
JP2023525555A5 true JP2023525555A5 (https=) 2024-05-22
JP7827640B2 JP7827640B2 (ja) 2026-03-10

Family

ID=76181307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568853A Active JP7827640B2 (ja) 2020-05-12 2021-05-11 新規なil10アゴニストを含む治療剤
JP2025206113A Pending JP2026048706A (ja) 2020-05-12 2025-11-27 新規なil10アゴニストおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025206113A Pending JP2026048706A (ja) 2020-05-12 2025-11-27 新規なil10アゴニストおよびその使用方法

Country Status (12)

Country Link
US (3) US11673930B2 (https=)
EP (1) EP4149963A1 (https=)
JP (2) JP7827640B2 (https=)
KR (1) KR20230009430A (https=)
CN (1) CN115667290A (https=)
AU (1) AU2021270563A1 (https=)
BR (1) BR112022022899A2 (https=)
CA (1) CA3183151A1 (https=)
IL (1) IL298007A (https=)
MX (1) MX2022014239A (https=)
WO (1) WO2021231447A1 (https=)
ZA (1) ZA202210918B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719458A2 (en) * 2023-06-01 2026-04-08 Synthekine, Inc. Il10 inverted monomers

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9824437D0 (en) 1998-11-06 1999-01-06 Ylo Herttuala Seppo Gene therapy
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
WO2005049094A1 (en) 2003-11-13 2005-06-02 Advantagene, Inc. A mixed complementary viral vector for gene therapy
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2007061657A2 (en) 2005-11-14 2007-05-31 The Brigham & Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
EP1991577A2 (en) * 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2008025032A1 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Soluble il-27 receptor
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
WO2017087784A1 (en) 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
AU2017257254B2 (en) * 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2017210684A1 (en) 2016-06-03 2017-12-07 New York University Methods and reagents for modulating macrophage phenotype
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
WO2018144784A1 (en) 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
IL272635B2 (en) * 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
US20200353050A1 (en) * 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
US12109249B2 (en) * 2018-01-30 2024-10-08 University Of Louisville Research Foundation Compositions and methods for treating inflammation and cancer
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020097946A1 (zh) 2018-11-18 2020-05-22 杭州博虎生物科技有限公司 一种重组人白细胞介素10融合蛋白及其应用
EP3927728A2 (en) * 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
US20220227827A1 (en) * 2019-03-25 2022-07-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
WO2020212598A1 (en) * 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
JP2023514152A (ja) * 2020-02-06 2023-04-05 ブリストル-マイヤーズ スクイブ カンパニー Il-10およびその使用

Similar Documents

Publication Publication Date Title
EP3638700B1 (en) Proteinaceous heterodimer and use thereof
AU2026200173A1 (en) Activatable Cytokine Constructs And Related Compositions And Methods
CN112534052B (zh) 全新il-21前药及使用方法
US11905322B2 (en) Engineered PD-1 variants
JP2023518518A5 (https=)
CN111527109A (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
AU2015255834B2 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP4017594A1 (en) Novel il-21 prodrugs and methods of use thereof
WO1996010089A1 (en) Modification of peptide and protein
JP2006006339A (ja) サイトカインの免疫複合体
JP2023534636A5 (https=)
JP2023123649A5 (https=)
EP4019536A1 (en) Immunocytokine, preparation for same, and uses thereof
HRP20030192A2 (en) Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug
WO2022165443A1 (en) Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
EP3688036A1 (en) Proteinaceous heterodimer and use thereof
JPH04504363A (ja) 組換え抗体―毒素融合タンパク質
JP2022553292A5 (https=)
JP2022530742A5 (https=)
JP6473696B2 (ja) 組換え酵母形質転換体及びこれを用いた免疫グロブリンFc断片の生産方法
CN107226866A (zh) 一种抗cd24人源化抗体融合蛋白
CN120590542A (zh) 基于clec9a的嵌合蛋白复合物
JP2023525555A5 (https=)
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
WO2023217288A1 (zh) 新融合蛋白及其用途